DG-041,99.15%

产品编号:Bellancom-10835| CAS NO:861238-35-9| 分子式:C23H15Cl4FN2O3S2| 分子量:592.32

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-10835
1250.00 杭州 北京(现货)
Bellancom-10835
1980.00 杭州 北京(现货)
Bellancom-10835
6880.00 杭州 北京(现货)
Bellancom-10835
11000.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

DG-041

产品介绍 DG-041 是一种有效,高亲和力,选择性的 EP3 受体拮抗剂,在结合和 FLIPR 试验中,IC50 分别为 4.6 nM 和 8.1 nM。DG-041 抑制 PGE2 促进血小板聚集。DG-041 可以穿过血脑屏障。
生物活性

DG-041 is a potent, high affinity and selective EP3 receptor antagonist with IC50s of 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively. DG-041 inhibits PGE2 facilitation of platelet aggregation. DG-041 crosses the blood-brain barrier.

体外研究

DG-041 was a less potent antagonist of the DP1 (IC50=131 nM), EP1 (IC50=486 nM), and TP receptors (IC50=742 nM).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

DG-041 (1.78 mg/kg for intravenous or 9.62 mg/kg for oral) has t1/2 of 2.7 hours, 4.06 hours and Cmax of 9.46 μM, 2.74 μM for intravenous and oral administration, respectively. DG-041 has CL of 1250 mL/h/kg for intravenous.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male SpragueDawley rat
Dosage: 1.78 mg/kg (intravenous) or 9.62 mg/kg (oral)
Administration: Intravenous or oral
Result: Had t1/2 of 2.7 hours, 4.06 hours and Cmax of 9.46 μM, 2.74 μM for intravenous and oral administration, respectively.
体内研究

DG-041 (1.78 mg/kg for intravenous or 9.62 mg/kg for oral) has t1/2 of 2.7 hours, 4.06 hours and Cmax of 9.46 μM, 2.74 μM for intravenous and oral administration, respectively. DG-041 has CL of 1250 mL/h/kg for intravenous.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male SpragueDawley rat
Dosage: 1.78 mg/kg (intravenous) or 9.62 mg/kg (oral)
Administration: Intravenous or oral
Result: Had t1/2 of 2.7 hours, 4.06 hours and Cmax of 9.46 μM, 2.74 μM for intravenous and oral administration, respectively.
性状Solid
溶解性数据
In Vitro: 

DMSO : 250 mg/mL (422.07 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.6883 mL 8.4414 mL 16.8828 mL
5 mM 0.3377 mL 1.6883 mL 3.3766 mL
10 mM 0.1688 mL 0.8441 mL 1.6883 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (3.51 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.51 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液
*以上所有助溶剂都可在 西域 网站选购。
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服